InMed
is a Canada-based biopharmaceutical company that researches and develops cannabinoids for the treatment of glaucoma and Alzheimer’s diseases... Read moreInMed
is a Canada-based biopharmaceutical company that researches and develops cannabinoids for the treatment of glaucoma and Alzheimer’s diseases... Read more
News
Feb 13, 2025
Seeking Alpha
InMed: InMed Pharmaceuticals GAAP EPS of -$3.64, revenue of $1.11M
Feb 13, 2025
Owler
Inmed Pharmaceuticals, Inc.: InMed's revenue changed from $4.96M in Sep 2024 to $4.83M in Dec 2024
Feb 13, 2025
FinanzNachrichten
InMed: InMed Pharmaceuticals: InMed Reports Second Quarter Fiscal 2025 Financial Results and Provides Business Update
Feb 03, 2025
FinanzNachrichten
InMed: InMed Pharmaceuticals: InMed Announces INM-089 Intravitreal Formulation in the Treatment of Dry Age-Related Macular Degeneration
Jan 22, 2025
FinanzNachrichten
InMed: InMed Pharmaceuticals Announces Granting of Patent for Novel Compounds
Jan 21, 2025
FinanzNachrichten
InMed: InMed Pharmaceuticals: InMed's INM-901 Demonstrates Statistically Significant Reduction in Neuroinflammation in a Long-Term Preclinical Alzheimer's Disease Study
Jan 21, 2025
Benzinga
InMed: Why InMed Pharmaceuticals (INM) Stock Is Skyrocketing
Dec 19, 2024
FinanzNachrichten
InMed: InMed Pharmaceuticals: InMed Announces Results of 2024 Annual General Meeting
Dec 17, 2024
FinanzNachrichten
InMed: InMed Pharmaceuticals: InMed Enters Into Standby Equity Purchase Agreement
Nov 19, 2024
FinanzNachrichten
InMed: InMed Pharmaceuticals: InMed Announces Publication of Study on Anti-Inflammation by Modulation of Endocannabinoid System
